Genmab — December 2022
-
oseph Mikhael
@jmikhaelmd
master presenter Ajai Chari presenting Talquetamab a bispecific antibody targeting GPRC5D. Amazing 74% ORR and even more remarkable low infection rates grade 3/4 at 17% and 12%. This is remarkable and may likely be the next bispecific and First GPRC5D available https://twitter.com/jmikhaelmd/status/1601640239877222403 -
Ben Derman
@bdermanmd
·
11 t
Rub some ‘DRT’ on it. MajesTEC-2 with Dara/Len/Tec. ORR 93.5% in a less refractory population with high rates of CR (55%). No data on mrd negativity among the CR population. But definitely makes a case for combination strategies for teclistamabhttps://twitter.com/bdermanmd/status/1601652148151779328 -
MyelomaTeacher - Cindy Chmielewski
@MyelomaTeacher
Hope - for RRMM
https://twitter.com/MyelomaTeacher/status/1601641808064581633 -
Jim Omel
@IMFjimMYELOMA
More Than 70% of Heavily Pretreated Patients Taking Talquetamab for Multiple Myeloma See Responses That “Deepen Over Time” https://ajmc.com/view/70-of-heavily-pretreated-patients-taking-talquetamab-for-multiple-myeloma-see-responses-that-deepen-over-time-
via @AJMC_Journal
More exciting immunotherapy news from ASH. 70% response to a new myeloma cell surface target. https://twitter.com/IMFjimMYELOMA/status/1601748849156321280 -
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI (teclistamab-cqyv) in Combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma https://www.janssen.com/janssen-presents-first-data-majestec-2-trial-tecvayli-teclistamab-cqyv-combination-darzalex-faspro
-
Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma https://www.janssen.com/janssen-presents-new-data-talquetamab-first-class-gprc5dxcd3-bispecific-antibody-suggesting-durable
-
It's a while ago this was written 'Assuming epco gets approved, and 1 biontech duobody, then for these first 9 Genmab approved antibodies, 8 of them will be blockbusters, Kesimpta will be multiple blockbuster, Teclistamab, Talquetamab, Tepezza now are prognosed for >$4bn and Dara and Rybrevant >$5bn. That is just unheard of for a biotech.' but seems fully on track... maybe Mim8 will be #9 though, as GB suggested or even Inclacumab...
-
Ash 2022 – talquetamab heads to the regulators https://www.evaluate.com/vantage/articles/events/conferences-trial-results/ash-2022-talquetamab-heads-regulators
-
PET scan for Richters / epco https://twitter.com/asernapareja/status/1601716206050115584/photo/1
-
https://www.youtube.com/watch?v=8yirKYro2cw talquetamab
-
-
@Bulder. Jan will probably say it is a Janssen product, and refer the analyst to them.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind